| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2426 | 2009 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National cancer Institute 103 (22), 1656-1664, 2011 | 2155 | 2011 |
| Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk HK Meier-Ewert, PM Ridker, N Rifai, MM Regan, NJ Price, DF Dinges, ... Journal of the American College of Cardiology 43 (4), 678-683, 2004 | 1486 | 2004 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1355 | 2017 |
| Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ... The lancet oncology 14 (4), 297-305, 2013 | 1354 | 2013 |
| Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ... Journal of Clinical Oncology 38 (12), 1346-1366, 2020 | 1150 | 2020 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1148 | 2013 |
| Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Q Wang, W Li, Y Zhang, X Yuan, K Xu, J Yu, Z Chen, R Beroukhim, ... Cell 138 (2), 245-256, 2009 | 1092 | 2009 |
| Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma DF McDermott, MM Regan, JI Clark, LE Flaherty, GR Weiss, TF Logan, ... Journal of clinical oncology 23 (1), 133-141, 2005 | 1071 | 2005 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 1040 | 2018 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ... New England Journal of Medicine 371 (2), 107-118, 2014 | 959 | 2014 |
| Adjuvant ovarian suppression in premenopausal breast cancer PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ... New England Journal of Medicine 372 (5), 436-446, 2015 | 910 | 2015 |
| The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer MM Pomerantz, N Ahmadiyeh, LI Jia, P Herman, MP Verzi, ... Nature genetics 41 (8), 882-884, 2009 | 797 | 2009 |
| Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline LA Korde, MR Somerfield, LA Carey, JR Crews, N Denduluri, ES Hwang, ... Journal of Clinical Oncology 39 (13), 1485-1505, 2021 | 775 | 2021 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 716 | 2018 |
| Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, ... Annals of Oncology 30 (10), 1541-1557, 2019 | 681 | 2019 |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ... Annals of oncology 32 (10), 1216-1235, 2021 | 674 | 2021 |
| Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy … G Viale, MM Regan, E Maiorano, MG Mastropasqua, P Dell'Orto, ... Journal of Clinical Oncology 25 (25), 3846-3852, 2007 | 553 | 2007 |
| Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer M Atkins, M Regan, D McDermott, J Mier, E Stanbridge, A Youmans, ... Clinical cancer research 11 (10), 3714-3721, 2005 | 534 | 2005 |
| Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical … MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ... The lancet oncology 12 (12), 1101-1108, 2011 | 496 | 2011 |
Giuseppe VialeUniversità di Milano e Istituto Europeo di OncologiaPotvrđena adresa e-pošte na ieo.it
